Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Dosing begins in NIH-funded phase II proof-of-concept study of ANS-6637

Oct. 18, 2019

AstraZeneca initiates first-in-human study of AZD-4041 in healthy volunteers

Oct. 15, 2019

Humanetics' development of radioprotectant BIO-301 supported by DoD cooperative research agreement

Oct. 2, 2019

NIDA grant supports Kinoxis' development of KNX-100 for opioid withdrawal

Oct. 1, 2019

Emergent BioSolutions, Indivior win NIH grants to study drugs for opioid use disorder

Sep. 30, 2019

NIDA award to support Ensysce's development of opioid use disorder product

Sep. 27, 2019

Omeros presents promising phase I results for PDE7 inhibitor OMS-182399 for addiction

Sep. 18, 2019

Preclinical characterization of novel mGlu2 receptor PAMs for the treatment of substance abuse

Sep. 10, 2019

A novel preclinical model of cocaine and alcohol coabuse

Sep. 6, 2019

Discovery of a selective OX1 receptor antagonist for substance abuse and dependency

Sep. 5, 2019

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...